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In vivo capture and label-free detection of early
metastatic cells
Samira M. Azarin1, Ji Yi2, Robert M. Gower3, Brian A. Aguado2, Megan E. Sullivan4, Ashley G. Goodman5,
Eric J. Jiang5, Shreyas S. Rao5, Yinying Ren5, Susan L. Tucker6, Vadim Backman2,7,8, Jacqueline S. Jeruss9,10 &
Lonnie D. Shea5,11,12,13
Breast cancer is a leading cause of death for women, with mortality resulting from metastasis.
Metastases are often detected once tumour cells affect the function of solid organs, with a
high disease burden limiting effective treatment. Here we report a method for the early
detection of metastasis using an implanted scaffold to recruit and capture metastatic cells
in vivo, which achieves high cell densities and reduces the tumour burden within solid organs
10-fold. Recruitment is associated with inﬁltration of immune cells, which include
Gr1hiCD11bþ cells. We identify metastatic cells in the scaffold through a label-free detection
system using inverse spectroscopic optical coherence tomography, which identiﬁes changes
to nanoscale tissue architecture associated with the presence of tumour cells. For patients at
risk of recurrence, scaffold implantation following completion of primary therapy has the
potential to identify metastatic disease at the earliest stage, enabling initiation of therapy
while the disease burden is low.
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T
he discovery of metastatic spread of a primary tumour is
often associated with poor prognosis, owing to the fact
that metastases typically go undetected until the function
of one or more organs have been affected. Identiﬁcation of
metastasis before signiﬁcant organ invasion would enable
interventional strategies to halt disease progression while the
disease burden is still low1. Much attention has been focused on
screening for the presence of circulating tumour cells (CTCs) as a
measure of metastasis. CTCs are present at low numbers in the
blood and technologies such as microﬂuidic devices have been
designed to capture and quantify the number of CTCs from
patient blood samples2,3. Recently, a system that also enables
expansion of CTCs following capture has been developed4.
These technologies provide opportunities for studying the
biology of CTCs, development of biomarkers, disease
monitoring and personalized medicine strategies. However,
CTCs can remain in the circulation for long periods of time
before homing to and colonizing a metastatic site, with some
tumour cells being shed at early points during tumour
progression5,6. Thus, we sought to develop a method for
capturing and detecting cells that have extravasated and
colonized a site, which are steps in the metastatic cascade
downstream from the circulation of tumour cells.
Paget’s seed-and-soil hypothesis, developed a century ago,
proposed that dissemination of cancer cells to speciﬁc sites in
the body, such as lung or liver, is not random but rather is due to
the receptive microenvironments at those sites7. More recently,
studies have shown that before colonization of a metastatic site, a
‘pre-metastatic niche’ is established by VEGFR1þ bone marrow-
derived hematopoietic progenitor cells8. These cells create a
tumour-supportive microenvironment comprised of several cell
types, including hematopoietic and endothelial progenitor
cells and immune cells that condition the environment with
matrix proteins, cytokines and chemokines to facilitate migration,
invasion, proliferation and angiogenesis at the metastatic site9–11.
Immune cells, in particular, play critical roles in homing
and colonization of the metastatic site. Macrophages facilitate
extravasation of metastatic cells as they begin the process
of colonization12. Myeloid-derived suppressor cells13–15 and
inﬂammatory monocytes16 have also been associated with
metastatic sites, and neutrophils have been shown to facilitate
transendothelial migration of tumour cells. Importantly, the
existence of the pre-metastatic niche indicates that a site could
be engineered to recapitulate the microenvironment of the niche
in vivo.
In this report, we develop a biomaterial implant to recruit and
capture metastatic cells, combined with an imaging system using
inverse spectroscopic optical coherence tomography (ISOCT) for
label-free detection of cancer cells at the implant, that together
constitute a system to detect early metastases. The implants are
microporous scaffolds composed of poly(lactide-co-glycolide)
(PLG), a material that is FDA approved for a variety of
applications. We also investigate if the capture of extravasating
metastatic cells can reduce colonization of solid organs and
consequently tumour burden, which could have therapeutic
implications. In addition, modulation of the local immune
environment may be a versatile approach for recruiting tumour
cells that is distinct from strategies that mimic the micro-
environment of a target organ, such as bone17,18. To this end,
the immune response at the implant, which consists of
numerous cell types such as macrophages and neutrophils, is
hypothesized to mediate recruitment of tumour cells8,10,12,16,19,20,
and this mechanism of recruitment is investigated through
localized delivery of the chemokine CCL22 and transplantation
of myeloid-derived suppressor cells. Recruited tumour-associated
myeloid-derived suppressor cells, in part, contribute to the
formation a pre-metastatic niche, which supports a permissive
environment for the capture of tumour cells in the scaffold.
This approach for immune cell-mediated capture and early
detection of metastatic cells has the potential to be broadly
applicable to many types of cancer.
Results
Scaffolds for in vivo capture of metastasizing cells. An
orthotopic model of human breast cancer metastasis was
employed to investigate the capture of metastatic cells at a
biomaterial implant. tdTomato- and luciferase-expressing
MDA-MB-231BR (231BR) cells, a highly metastatic variant of
the MDA-MB-231 cell line21, were transplanted into the right
mammary fat pads of female NOD/SCID-IL2Rg / (NSG) mice
(Fig. 1c). One week after tumour inoculation, microporous
PLG scaffolds (5-mm diameter, 2-mm height, Supplementary
Fig. 1a–c) were implanted into the peritoneal fat pads, a site
to which 231BR cells are not reported to colonize, yet supports
the vascularization of PLG scaffolds. Bioluminescence imaging
and histological analysis of peritoneal fat pads removed 28 days
after tumour inoculation demonstrated the presence of tumour
cells within the implanted PLG scaffold (Fig. 1a,d) and the
absence of tumour cells in fat pads without scaffolds (Fig. 1b,e),
indicating that the local environment generated by implantation
of the scaffold enabled recruitment of metastatic cells. Primary
tumour growth was not affected by either implantation of
scaffolds or a mock surgery (Supplementary Fig. 2). Staining for
ﬁbronectin, a matrix protein reported to be involved in
establishment of the pre-metastatic niche8, indicated that
ﬁbronectin was present in scaffolds implanted in both
healthy and tumour-bearing mice as early as 7 days post
implantation (Supplementary Fig. 1d). Interestingly, recruitment
of cells to the scaffold was not site-speciﬁc, as tumour cells were
detected in scaffolds implanted in the subcutaneous tissue
(Supplementary Fig. 3).
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Figure 1 | PLG scaffolds recruit metastatic tumour cells. Tissues were isolated at day 28 post-tumour inoculation (21 days after scaffold implantation or
mock surgery). (a,b) Bioluminescence imaging (BLI) of peritoneal fat pads receiving scaffold implants (a) or mock surgeries (b). (c-e) Hematoxylin and
eosin (H&E) staining of the primary tumour (c) a fat pad containing a scaffold (white circle indicates metastatic cluster) (d) and a fat pad without a scaffold
(e). Scale bars, 100 mm.
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Scaffolds reduce tumour burden in solid organs. We
subsequently investigated whether capturing tumour cells in
scaffolds would reduce colonization of standard metastatic sites,
such as the lung and liver. At 28 days post-tumour inoculation,
the relative abundance of tumour cells, reported as the ratio
of tdTomato-positive tumour cells to total cells, was determined.
For mice that received scaffolds, the relative abundance of
tumour cells in the lung was 1:5,400, compared with 1:645 for
mice receiving a mock surgery (Fig. 2a, Supplementary Fig. 4).
Thus, the presence of a scaffold reduced the tumour burden for
the lung by 88±7% (average±s.e.m.). Histological analysis of
lung sections conﬁrmed a reduction in the tumour cell
burden with scaffold implantation (Fig. 2b,c), with an average
of 1.7±0.5 metastatic lesions per section observed in the lungs of
scaffold-bearing mice, compared with 5.5±1.7 lesions per section
in mice receiving mock surgeries. Furthermore, ﬂow cytometric
analysis of cells isolated from the liver showed detectable tumour
cells in eight out of eight mice receiving mock surgeries, while
mice receiving scaffold implants only exhibited detectable tumour
cells in two of eight livers (Po0.01, Fisher’s exact test).
Early detection of tumour cells in scaffold. The potential to use
scaffolds for early detection of metastasis was determined by
quantifying the percentage of tumour cells in intraperitoneal and
subcutaneous scaffolds compared with the lung and liver at day
14 post-tumour inoculation. In a group of eight mice, most
intraperitoneal scaffolds (15/16) contained tumour cells at this
time point, while none of the mice had detectable tumour cells in
the lung and liver (Fig. 3a). In a separate group of mice, all
subcutaneous scaffolds (10/10) contained tumour cells. The
incidence of detectable metastatic disease at this early time point
was lower than at day 28 post-tumour inoculation. At day 28
post-tumour inoculation in scaffold-bearing mice, the lung
and liver exhibited tumour cells in 8 and 2 of the eight
mice, respectively. Furthermore, for mice receiving mock
surgeries instead of scaffold implants, the incidence of
metastatic cells in both the lung and liver increased to eight out
of eight mice. Importantly, at day 14 post inoculation, while none
of the lungs and livers exhibited detectable tumour cells, both
intraperitoneal and subcutaneous scaffolds had a detectable
percentage of tumour cells (0.019±0.005% for intraperitoneal
scaffolds and 0.044±0.017% for subcutaneous scaffolds) (Fig. 3b,
Supplementary Fig. 5). This ability to detect tumour cells in the
scaffold before detection in the lungs and liver may enable the
early detection of metastatic disease through imaging the scaffold.
Label-free detection of metastasis at the scaffold. ISOCT22 was
applied to directly visualize the scaffold architecture and provide
quantitative measurement of the ultrastructural changes induced
by the cancer cells. ISOCT is a light scattering-based technique
capable of non-invasive three-dimensional (3D) imaging of tissue
morphology with micron-level resolution and millimeter-level
penetration depth23,24. In addition, for each 3D resolution voxel
(15 15 2 mm) ISOCT also performs a spectroscopic analysis
and quantiﬁes the power of the spectra by a scattering model
I(l)plD-4 22. D is the shape factor that physically deﬁnes the
macromolecular density correlation function for a range of length
scales from B40 to 350 nm (ref. 25), with higher D values
indicating a more clumped structure. It has been demonstrated
that D is a ubiquitous marker of the ultrastructural alterations in
the early stages of various cancer types despite their different
etiologies26–30, with both neoplastic cells and the surrounding
stroma exhibiting an increase in D in part due to chromatin
condensation and collagen remodelling, respectively27,30,31.
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Figure 2 | Recruitment of tumour cells to scaffolds reduces tumour burden in lung. (a) Flow cytometric analysis of the percentage of tdTomato-positive
tumour cells in cells isolated from lungs at day 28 post-tumour inoculation. Data shown as mean±s.e.m. (n¼8, 2 independent biological replicates).
*Po0.01 compared with mock surgery (Mann–Whitney test). (b) H&E staining of lung section (black circles indicate metastatic clusters). Scale bar,
200mm. (c) Histological analysis of H&E-stained lung sections to determine the number of tumour clusters per section. Data shown as mean±s.e.m.
(n¼ 12, 2 independent biological replicates). *Po0.05 compared with mock surgery (Mann–Whitney test).
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Figure 3 | Early detection of tumour cells in scaffolds. Flow cytometric analysis of tdTomato-positive tumour cells in tissues isolated from mice at day 14
and 28 post-tumour inoculation. (a) Number of mice with tumour cells detectable in each tissue in a group of 8 mice at day 14 or 28 post-tumour
inoculation. Each mouse received two intraperitoneal (IP) scaffolds. P values from Fisher’s exact test. (b) Percentage of tdTomato-positive cells in the total
cell population isolated from IP scaffolds and subcutaneous (SQ) scaffolds at day 14 post-tumour inoculation. Data shown as mean±s.e.m. (n¼ 16 for IP
scaffold, n¼ 10 for SQ scaffold, two independent biological replicates). *Po0.05 compared with IP scaffold (Mann–Whitney test).
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Given the nanoscale sensitivity of measuring D and the tissue-
level imaging capability, we hypothesized that ISOCT could be an
effective approach for detection of cancer cells within the scaffold.
In vitro studies were performed to demonstrate that ISOCT
could capture changes in D for cells and matrices, and the
technique was subsequently applied to in situ imaging of
scaffolds. ISOCT analysis of 231BR cell pellets conﬁrmed that
they had a higher D than normal mammary epithelial cells
(MCF10A) and cells isolated from lungs of tumour-free NSG
mice (3.49±0.12, 2.74±0.15 and 3.00±0.13, respectively,
Supplementary Fig. 6a). Changes to collagen remodelling by
231BR cells were evaluated by culturing 231BR cells in collagen
gels for 3 days, after which cells were extracted and the gels were
analysed using ISOCT. 231BR-conditioned matrices exhibited a
D value of 1.69±0.08 compared with a D value of 1.29±0.04
for gels cultured with media (Supplementary Fig. 6b). With
conﬁrmation of the technique in vitro, in situ ISOCT analysis was
applied to scaffolds, which demonstrated that scaffolds implanted
in the subcutaneous tissue of tumour-bearing mice also had an
increase in D at day 14 post-tumour inoculation compared with
control scaffolds in tumour-free mice (Fig. 4), with an average
D value of 5.77±0.38 in tumour-bearing mice compared with
4.71±0.17 in tumour-free mice. This increase in D is consistent
with the changes associated with the presence of cancerous cells
and the ensuing reorganization of the extracellular matrix. These
results indicate that this method can be used for label-free
detection of micrometastases within the scaffold at the early
stages of metastatic disease.
Immune cells contribute to tumour cell recruitment. Given the
critical role of various immune cells types in establishing
the pre-metastatic niche8,10,12,16,19,20, we hypothesized that the
immune response to the scaffold was mediating recruitment of
tumour cells. For analysis of the immune environment within the
scaffolds, we used an immune-competent mouse model in
addition to the NSG model to account for effects of both the
innate and adaptive immune response. Scaffolds implanted into
BALB/c mice inoculated with 4T1 mouse breast cancer cells
also demonstrated metastatic cells within the scaffold, indicating
that the scaffold could still achieve homing within the context of
an intact immune system (Supplementary Fig. 7).
Inﬂammatory cells proposed to be involved in recruiting tumour
cells were characterized within the peritoneal fat pads of mice in
the presence and absence of a scaffold. A high density
of CD45-positive leukocytes was present in histological sections
of the scaffold, with no observed CD45-positive leukocytes present
in fat pads of mice receiving mock surgeries (Fig. 5a,b). The ability
of CD45-positive leukocytes to inﬂuence homing of tumour cells
was investigated through migration assays using media condi-
tioned by splenocytes isolated from spleens of tumour-bearing
mice, as the spleen contains a large number of immune cells and
has a distribution of immune cells similar to the scaffolds, with the
predominant cell type being Gr1hiCD11bþ cells (Supplementary
Fig. 8). Migration of both cell types was signiﬁcantly increased
in the presence of splenocyte-conditioned media relative to
unconditioned media (Fig. 5c,d), with 261±35 migrating 231BR
cells per well in conditioned media compared with 137±20 cells in
unconditioned media and 521±22 migrating 4T1 cells per well in
conditioned media compared with 292±23 cells in unconditioned
media. These results indicate that paracrine signalling from
immune cell populations similar to those present in the scaffold
can induce migration of tumour cells.
Before and after the introduction of cancer cells, we analysed
the local immune environment of the implanted scaffold, which
was compared with that of the lung, a common site of breast
cancer metastasis. Flow cytometric analysis demonstrated that
during disease progression, the most notable change in the
relative distribution of immune cells was an increase in
Gr1hiCD11bþ cells (Fig. 5e–h, Supplementary Figs 9–11). This
increase was consistent in both the NSG and BALB/c mouse
models, and was found in both the lungs and scaffolds. In the
lungs of the NSG mice, the percentage of Gr1hiCD11bþ cells
increased from 45±2% at day 0 (no tumour) to 52±3% at
day 14 post-tumour inoculation, to 84±1% at day 28
post-tumour inoculation (Fig. 5e). Following this trend, the
percentage of Gr1hiCD11bþ cells found in the scaffolds from
the NSG mice increased from 21±1% (tumour-free mice), to
35±5% at day 14 post-tumour inoculation, to 62±2% at day 28
post-tumour inoculation (Fig. 5g). In the lungs of BALB/c mice,
Gr1hiCD11bþ cells increased from 1±0.1% at day 0 (tumour-
free mice) to 57±1% at day 14 post-tumour inoculation, to
89±2% at day 28 post-tumour inoculation (Fig. 5f). Likewise,
within the scaffolds from the BALB/c mice, Gr1hiCD11bþ cells
increased from 0.1±0.01% (no tumour) to 32±3% at day 14
post-tumour inoculation, to 66±5% at day 28 post-tumour
inoculation (Fig. 5h). These results highlight the correlation
between disease exposure time and the relative abundance of
Gr1hiCD11bþ cells found in both the lungs and scaffolds of
affected animals, and show that the immune environment
within a metastatic organ site is similar to that of an implanted
scaffold.
We subsequently investigated the hypothesis that modulation
of the inﬂammatory microenvironment within the scaffold site
would inﬂuence recruitment of metastatic cells. Lentiviral vectors
were delivered from the scaffold to promote localized transgene
expression for the duration of the study (Supplementary Fig. 12).
The chemokine CCL22 was selected for expression as it
induces migration of splenocytes harvested from NSG mice
(Supplementary Fig. 13a) yet does not inﬂuence the migration of
tumour cells (Supplementary Fig. 13b). Flow cytometric analysis
of CCL22 scaffolds at day 7 post implantation indicated an
increase in Gr1hiCD11bþ cells, which have been implicated in
the pre-metastatic niche10,14,15, from 20±2% to 29±3% in NSG
D D
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Figure 4 | Detection of tumour cells in scaffold using ISOCT. (a,b) Representative 3D maps of D generated from in situ ISOCT analysis of subcutaneous
scaffolds implanted in tumour-free (a) and tumour-bearing (b) mice at day 14 post-tumour inoculation. Scale bars, 200 mm. (c) Average D value for
subcutaneous scaffolds in tumour-free (‘No Tumor’) and tumour-bearing (‘Tumor’) mice. Data shown as mean±s.e.m. (n¼6, 2 independent biological
replicates). *Po0.05 compared with tumour-free mice (Mann–Whitney test).
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mice and from 14±1% to 19±1% in BALB/c mice (Fig. 6a,c). In
addition, F4/80þCD11bþ inﬂammatory macrophages, which are
recruited to circulating metastatic cells as they undergo
extravasation and begin colonization12, increased from 28±2%
to 34±2% in the NSG model and from 10±1% to 14±1% in the
BALB/c model (Fig. 6a,c). Furthermore, CCL22 expression
increased the number of tdTomato-positive tumour cells
present in the scaffold in both mouse models at day 7 post
implantation (day 14 post-tumour inoculation), with an average
of 92±16 cells compared with an average of 23±4 cells for
b-galactosidase expression in NSG mice and an average of 62±5
cells compared with an average of 20±2 cells for b-galactosidase
expression in BALB/c mice (Fig. 6b,d).
A cell population upregulated by CCL22 delivery,
Gr1hiCD11bþ cells, was next transplanted on the scaffold to
directly modulate the local immune environment and
further demonstrate that the immune environment mediates
metastatic cell recruitment. Gr1hiCD11bþ cells were selected for
these studies given their established role in the pre-metastatic
niche, along with migration assays showing soluble factors
secreted by Gr1hiCD11bþ cells isolated from spleens of
tumour-bearing NSG mice induced migration of 231BR cells
(Fig. 6e). Interestingly, the Gr1hiCD11bþ cells induced migration
to a greater extent than splenocyte-conditioned media
(Supplementary Fig. 14). Implantation of scaffolds seeded with
Gr1hiCD11bþ cells signiﬁcantly increased the percentage of
Gr1hiCD11bþ cells in the total leukocyte population (from 20±2
to 26±2%, Fig. 6f) as well as the number of tumour cells (from
29±10 to 74±13 cells, Fig. 6g) present per scaffold, indicating
that Gr1hiCD11bþ cells contributed to recruitment of tumour
cells to the scaffold.
Discussion
This study demonstrates a platform technology for the capture
and label-free detection of cancer cells early in the onset of the
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Figure 5 | Evaluation of the immune environment within scaffolds. (a,b) CD45 immunolabeling (green) at day 28 post-tumour inoculation of fat pads
receiving mock surgery (a) or scaffold implant (b). Nuclei are blue. Scale bar, 100 mm. (c,d) Number of migrating 231BR (c) or 4T1 (d) cells in the presence
of splenocyte-conditioned media (SCM) or non-conditioned media (non-SCM). Data shown as mean±s.e.m. (n¼ 6, 2 independent biological replicates).
*Po0.05 and **Po0.005 compared with non-conditioned media (Mann–Whitney test). (e–h) Flow cytometric analysis of cells removed from lungs (e,f)
and scaffolds (g,h) of tumour-free and tumour-bearing (day 14 and 28) NSG (e,g) or BALB/c (f,h) mice. The model used for mice with tumours involved
the inoculation of tumour cells at day 0, with scaffolds implanted at day 7. The evaluation of scaffolds in tumour-free mice was performed on day 7 post
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metastatic process. Biomaterial scaffolds were engineered to
recruit metastatic cells in vivo through modulation of the local
immune environment, with detection of cancer cells based on the
tissue nanoarchitecture by ISOCT. The ability of the scaffolds to
reduce tumour burden in host organs that are standard sites of
breast cancer metastasis suggests the potential use of the scaffold
as a therapeutic tool, serving as a sink to capture CTCs. As
opposed to models that employ tail vein injections to study lung
colonization by directly placing large numbers of tumour cells in
the bloodstream32, the orthotopic model employed in this study
more closely mimics the release of metastatic cells from the
primary tumour observed in the clinical setting. The ability of the
scaffolds to capture a fraction of the metastatic cells early in
disease progression and consequently limit colonization to other
organ sites is also a distinguishing feature from purely diagnostic
approaches, such as the detection of CTCs in blood samples.
Furthermore, cancer cells can be retrieved from scaffolds and
analysed for biomarkers unique to the metastatic setting, and
targeted therapies could then be developed that are appropriately
tailored to metastatic cancer cell biology.
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Figure 6 | Immunomodulation of the scaffold microenvironment inﬂuences recruitment of tumour cells. Flow cytometric analysis at day 14 post-tumour
inoculation of cells removed from scaffolds containing a CCL22 or b-galactosidase (control) vector implanted in NSG (a,b) or BALB/c (c,d) mice. Cell
populations are reported as percentage of total CD45-positive leukocytes (a,c) or total number of tumour cells in the scaffold (b,d). Data shown as
mean±s.e.m. (n¼ 10, 2 independent biological replicates). *Po0.05, **Po0.005 and ***Po0.001 compared with b-galactosidase scaffolds (Mann–
Whitney test). (e) Number of migrating 231BR cells in the presence of Gr1hiCD11bþ cell-conditioned media (Gr1hiCD11bþ CM) or non-conditioned media
(non-SCM). Data shown as mean±s.e.m. (n¼6, 2 independent biological replicates). ***Po0.001 compared with non-conditioned media (Mann–Whitney
test). (f,g) Flow cytometric analysis at day 14 post-tumour inoculation of cells removed from blank scaffolds or scaffolds seeded with Gr1hiCD11bþ cells.
Cell populations are reported as the percentage of Gr1hiCD11bþ cells in the total leukocyte population (f) or total number of tumour cells in the scaffold
(g). Data shown as mean±s.e.m. (n¼ 10, 2 independent biological replicates). *Po0.05 compared with blank scaffold (Mann–Whitney test).
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The approach of designing scaffolds to capture circulating cells
in vivo has been used for cancer as well as regenerative medicine
applications. Strategies to develop biomaterial implants that
capture endothelial progenitor cells and smooth muscle
progenitor cells from the bloodstream have been implemented
to promote vascularization of the implant33–35. In addition,
biomaterial scaffolds designed to recruit endogenous stem cells
have promoted bone regeneration36 and cardiac repair37.
Strategies to capture circulating cancer cells in vivo have
focused on mimicking the microenvironment of a target organ,
as demonstrated by the use of scaffolds that mimic the bone
microenvironment for capture of breast cancer cells18 and
hematopoietic cancer cells17. This technology used a broader
approach of recruiting metastasizing breast cancer cells through
local immune modulation, as immune cells have been shown to
play critical roles in recruiting metastatic cells9,10,12,14–16,19.
Given the importance of immune cells in regulating metastasis for
several cancers, this approach may provide a more versatile
method for capture of extravasating cancer cells in vivo. Further,
the coupling of cell capture strategies with label-free imaging
methods (that is, ISOCT) demonstrates the potential for using
this approach as a diagnostic tool.
These scaffolds also provide an enabling tool to control the cell
types and signals present at a local site to identify regulators of
early events in colonization, which could lead to novel therapeutic
targets for prevention of metastasis. The microenvironment
within the scaffolds can be modiﬁed through cell transplantation,
presentation of extracellular matrix proteins, or delivery of
proteins or gene therapy vectors38–41 and represents a platform
for molecularly dissecting the biological cues that underlie the
recruitment of metastatic cells. Herein Gr1hiCD11bþ cells were
either recruited through chemokine expression or transplanted
on the scaffold, which enhanced recruitment of extravasating
tumour cells. Gr1hiCD11bþ cells accumulate in the spleen during
tumour progression42, and previous reports indicate they are
recruited to a pre-metastatic niche by inﬂammatory
chemokines43. While the increase in Gr1hiCD11bþ cells in the
scaffold was modest, the increase in cancer cells was substantial,
which is consistent with multiple effects of Gr1hiCD11bþ cells on
tumour cells44.
Finally, scaffolds, coupled with ISOCT imaging, functioned as a
sensor to detect tumour cells early in the onset of metastatic
progression, which could enable therapeutic intervention while
the disease burden is low. While whole-body imaging techniques
do not provide the requisite sensitivity and resolution to detect a
few cells as they colonize a metastatic site, optical imaging is
suited for this application. Optical coherence tomography
(OCT) conventionally has been used to provide microscopic
reconstruction of tissue morphology with a spatial resolution on
the order of several microns. Accordingly, OCT has been applied
to in vivo imaging of the tumour microenvironment45. ISOCT
models tissue as a medium with a continuously ﬂuctuating
macromolecular mass density46. By measuring its optical
properties, the mass density correlation function can be
inversely recovered at each 3D voxel of spatial resolution22.
Moreover, because ISOCT uses the spectral information to
measure the self-interference within a resolution-limited voxel,
the length scale of sensitivity of ISOCT can be as small as
B35nm, far beyond the resolution limit of conventional
microscopy47–49. While the necessary penetration depth and
large volume of a solid organ such as the lung or liver would not
be well-suited for ISOCT-based detection of a small number of
colonizing cells, the scaffold concentrates metastatic cells in an
area beneath the skin, a site that is more readily accessible for
imaging. Thus, ISOCT provides a robust approach for identifying
the changes to the scaffold microenvironment on colonization by
metastatic cells. Taken together, the early detection, reduced
burden of metastatic disease and potential to apply targeted
therapies afforded by this technology could signiﬁcantly extend
the time to disease progression.
Methods
Study design. The objective of the study was to use biomaterials scaffolds and
optical imaging techniques to capture and detect metastasizing breast cancer cells
in vivo. We hypothesized that due to the local inﬂammatory response following
implantation, the scaffolds become inﬁltrated with immune cells conducive to
recruiting metastatic cells, and that a light scattering-based imaging method could
detect changes to the tissue ultrastructure associated with arrival of the cancer cells.
Animal studies were performed with at least two independent replicates of 4–8
female 10–14-week-old mice per group with random assignment. Tissues were
analysed at day 14 or 28 post-tumour inoculation, with day 14 being the earliest
time point for detecting metastasis and day 28 being the ﬁnal time point, as the
primary tumour reached the maximum allowable size. In vitro experiments had
multiple samples that were independently repeated at least two times.
Tumour inoculation and volume measurement. Animal studies were performed
in accordance with institutional guidelines and protocols approved by the
Northwestern University Institutional Animal Care and Use Committee. Tumour
inoculation was performed by injecting 2 106 231BR (Northwestern University
Developmental Therapeutics Core) or 4T1 (ATCC) cells in a volume of 50 ml PBS
(Life Technologies) into the number four right mammary fat pads of 10 14-week-
old female NSG or BALB/c mice. NSG mice were purchased from The Jackson
Laboratory or bred in house. BALB/c mice were purchased from The Jackson
Laboratory. Tumour length and width were measured weekly using digital calipers
(VWR) beginning at day 14 post inoculation, and tumour volume was calculated
using the formula Volume¼ (Width2 Length)/2.
Scaffold fabrication and implantation. PLG scaffolds were fabricated as
previously described40. Brieﬂy, microspheres were prepared by emulsifying a 6%
solution of PLG (Lakeshore Biomaterials; 75:25 lactide:glycolide, inherent
viscosity¼ 0.76 dl g l) in dicholoromethane in 1% poly(vinyl alcohol).
Microspheres were washed four times with deionized water to remove residual
poly(vinyl alcohol) and lyophilized overnight. Next, microspheres were mixed with
250–425-mm salt particles in a 30:1 ratio and pressed in a steel die at 1,500 psi. The
scaffolds were then gas-foamed and salt particles were removed by washing in
water for 90min. Scaffolds were sterilized with 70% ethanol and rinsed with water
before drying. Incorporation of a viral vector was performed by incubating 1 109
viral particles in a volume of 10 ml PBS with the scaffold for 8min. In these studies,
tumours were inoculated at day 0 and scaffolds were implanted in the
intraperitoneal fat pads or subcutaneous space at day 7.
Virus production. The lentiviral vector of interest was co-transfected with the
packaging vectors pRSV-Rev, pIVS-VSV-G and pMDL-GagPol50 into HEK-293T
cells grown in DMEM (Sigma) containing 10% fetal bovine serum (Life
Technologies) for virus production using Lipofectamine 200 (Life Technologies).
After 48 h the supernatant was collected. Viral particles were concentrated using
PEG-it (Systems Biosciences) and resuspended in PBS. Virus titre was quantiﬁed
using the qPCR Lentivirus Titration Kit (Applied Biological Materials) according to
the manufacturer’s instructions.
Bioluminescence imaging. Five minutes before imaging, mice were injected
intraperitoneally with D-luciferin (Molecular Imaging Products; 20mgml 1 in
PBS) at 150mg kg 1 body weight. For whole-animal imaging, mice were anes-
thetized with inhaled isoﬂurane and in vivo luciferase expression was evaluated
using the IVIS Spectrum imaging system (Caliper Life Sciences). For imaging of
tissues, mice were euthanized 5min after injection with D-luciferin and tissues
were retrieved and imaged using the IVIS Spectrum.
Histological analysis and immunohistochemistry. Organs and implanted scaf-
folds were retrieved from mice, rinsed in PBS and then immediately ﬂash-frozen in
pre-chilled isopentane. The frozen tissue was then embedded in optimal cutting
temperature (OCT; Cardinal Health) compound with 30% sucrose. The lungs were
sectioned at 12 mm, and the scaffolds and fat pads were sectioned at 14-mm thick
sections using a cryostat (Microm HM 525; Microm International) and stored at
 20 C until staining. To determine the presence of tumour cells, slides were
ﬁxed with 4% paraformaldehyde (Sigma) for 10min and stained with Gill III
Hematoxylin (Leica) and Eosin Y (Leica). Blinded scoring of the number of tumour
clusters in each tissue section was performed by a pathologist. Two sections were
analysed per mouse, and in each of two separate experiments, sections from three
mice per group were analysed, for a total of six animals per condition. The sections
analysed were non-adjacent and separated by at least 5mm. For immunohisto-
chemistry, sections were ﬁxed for 12min in 4% paraformaldehyde and stained with
a polyclonal rabbit anti-CD45 primary antibody (1:100, Abcam) followed by a
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CF633 anti-rabbit secondary antibody (1:500, Sigma) or a polyclonal rabbit anti-
ﬁbronectin antibody (1:250, Abcam) followed by an Alexa Fluor 488 anti-rabbit
secondary antibody (1:500, Life Technologies). Nuclei were labelled with Hoechst
33250 (1:2,000, Invitrogen). Samples were imaged using a Leica SP5 II laser
scanning confocal microscope.
Flow cytometry. Mice were euthanized and tissues were retrieved, minced with
microscissors in a 0.38mgml 1 solution of Liberase TL or TM (Roche Applied
Science) in Hank’s Balanced Salt Solution (HBSS; Life Technologies) and placed at
37 C for 20min. Liberase was neutralized with 0.125M EDTA, and cells were
isolated by passing the digested tissue through a 70 mm ﬁlter (BD Biosciences)
and rinsing with FACS buffer, PBS containing 0.5% Bovine Serum Albumin
(BSA; Sigma) and 2mM EDTA (Life Technologies). Red blood cells were lysed
using ACK lysing buffer (Life Technologies). For analysis of tdTomato-positive
tumour cells, samples were resuspended in FACS buffer and analysed using an LSR
II ﬂow cytometer (Becton Dickinson Immunocytometry Systems, BDIS). A
standard curve was established for each organ by adding deﬁned numbers of
tumour cells into cells isolated from healthy lungs and livers and measuring the
number of tdTomato-positive cells via ﬂow cytometry. From this analysis, it was
determined that the threshold tumour cell density of 0.002% (ﬁve tumour cells in
250,000 total cells) was consistently and signiﬁcantly above background, and thus
samples were deemed to have detectable cancer cells if the tumour cell density was
above 0.002%. For analysis of leukocyte populations, cells were blocked with
anti-CD16/32 (1:50, eBioscience) and stained for viability using ﬁxable blue dead
cell stain kit (Life Technologies). Cells were then stained with Alexa Fluor
700-conjugated anti-CD45 (30-F11, 1:125; Biolegend), Paciﬁc Blue-conjugated
anti-Gr-1 (RB6-8C5, 1:70; Biolegend), FITC-conjugated anti-Ly-6C (HK1.4, 1:100;
Biolegend), PE-Cyanine7-conjugated anti-F4/80 (BM8, 1:70; Biolegend), APC-
conjugated anti-CD11c (N418, 1:85; eBioscience), v500-conjugated anti-CD11b
(M1/70, 1:100; BD Biosciences), Paciﬁc Blue-conjugated anti-CD19 (6D5, 1:100;
Biolegend), v500-conjugated anti-CD4 (RM4-5, 1:100; BD Biosciences),
FITC-conjugated anti-CD8a (53-6.7, 1:25; Biolegend) and PE-Cyanine7-conjugated
anti-CD49b (DX5, 1:40; Biolegend). Samples were analysed using an LSRFortessa
ﬂow cytometer (BDIS).
Splenocyte isolation for transplants and media conditioning. Spleens were
isolated from tumour-bearing mice, minced using microscissors and incubated in a
0.38mgml 1 solution of Liberase TL (Roche Applied Science) for 20min at 37 C.
The minced tissue was passed through a 70 mm strainer and red blood cells were
lysed using ACK lysing buffer (Life Technologies). To collect Gr1hiCD11bþ cells,
splenocytes were labelled with FITC-conjugated anti-Gr-1 (RB6-8C5, 1:100;
Biolegend), APC-conjugated anti-Ly-6C (HK1.4, 1:50; Biolegend), and APC-
eFluor780-conjugated anti-CD11b (M1/70, 1:100; eBioscience) and the
Gr1hiCD11bþLy6C population was collected via FACS sorting using a BD
FACSAria cytometer (BDIS). The remaining splenocyte population
(Gr1hiCD11bþ cell-depleted) was also collected. For cell transplantation studies,
scaffolds were rinsed with RPMI medium (Life Technologies) containing 5% fetal
bovine serum (FBS; Life Technologies) and dried on gauze. 1 106 Gr1hiCD11bþ
cells were seeded on each scaffold in a volume of 5 ml RPMI with 5% FBS and
scaffolds were implanted into the intraperitoneal fat pads. For generation of
conditioned media, splenocytes, Gr1hiCD11bþ cells, and Gr1hiCD11bþ
cell-depleted splenocytes were each plated at a concentration of 1 106 cells per ml
in RPMI media. Media was conditioned for 48 h, after which the media was
sterile-ﬁltered to remove splenocytes.
Splenocyte migration assays. Migration assays were performed in 24-well
transwell chambers with 5-mm pore size ﬁlters (Corning). A total of 1 106
splenocytes were placed in the top chamber in 100 ml of RPMI medium containing
10% FBS. 600 ml of RPMI medium containing 10% FBS with or without
100 ngml 1 recombinant mouse CCL22 (Peprotech) was placed in the bottom
chamber. After 1.5 h, the number of cells that had migrated to the bottom chamber
was counted using a hemocytometer.
Tumour cell migration assays. Tumour cells were serum-starved overnight in
DMEM (Sigma) or RPMI (Life Technologies) containing 0.2% FBS (Life technol-
ogies). Migration assays were performed in 24-well transwell chambers with 8-mm
pore size ﬁlters (Corning). Total of 5 104 231BR or 4T1 cells were placed in the
top chamber in 300 ml of DMEM (for CCL22 assays) or RPMI (for conditioned
media assays) containing 0.2% FBS. For CCL22 assays, 750 ml of DMEM containing
0.2% FBS with or without 100 ngml 1 recombinant human CCL22 or SDF1
(Peprotech) was placed in the bottom chamber. For conditioned media, 750 ml of
RPMI, splenocyte-conditioned RPMI, Gr1hiCD11bþ cell-conditioned RPMI or
RPMI conditioned with Gr1hiCD11bþ cell-depleted splenocytes was placed in the
bottom chamber (all media was supplemented with 0.2% FBS). After 24 h, the cells
on the top of the ﬁlter were removed by gently scrubbing with a cotton swab, and
the cells on the bottom of the ﬁlter were stained for 60min in a 0.5% (w/v) solution
of crystal violet (Sigma) in 60% PBS/40% ethanol. The inserts were rinsed in PBS
and the number of migrating cells was counted.
Conditioning collagen gels with 231BR cells. A 1.6mgml 1 collagen I solution
was prepared by mixing rat tail Collagen I (BD Biosciences) with deionized water,
10 PBS (Sigma, 1:10 dilution) and 1 N NaOH (Sigma, 1:1,000 dilution) on ice.
Collagen solution (150 ml) was placed in each well of a 48-well plate. Gels were
incubated at 37 C for 1 h, after which 1.875 105 231BR cells in 400 ml of RPMI
containing 10% FBS were seeded on each gel. Control gels received 400 ml of RPMI
containing 10% FBS. After incubation at 37 C for 3 days, cells were extracted from
the gels. The media was removed from each well and the gels were washed three
times with 1 PBS (Life Technologies). A 20mM NH4OH solution containing
0.5% (v/v) Triton X-100 (Sigma) was added to each well and the chamber slide was
incubated at 37 C for 5min. After removal of the NH4OH/Triton X-100 solution,
the gels were washed twice with distilled water and twice with PBS. A volume of
175 ml of PBS was added to each well before imaging.
Scanning electron microscopy. Structural characteristics of scaffolds were imaged
with a scanning electron microscope (Hitachi s4800-II cFEG s.e.m.; Hitachi High-
Technologies Corp.). A 15-nm gold coating was applied and the microscope was
operated at 2 kV.
ISOCT imaging and analysis. The OCT system used a Fourier domain
conﬁguration. A supercontinuum light source (NKT photonics, SuperK versa)
provided a broadband laser fromB500 to 840 nm. The spectral range from 650 to
830 nm was used for OCT image construction. The laser was delivered by an
optical ﬁbre, collimated by a lens, and input into a cube beam splitter (BS;
Thorlabs, CM1-BS013), by which the light was divided into a sample arm and a
reference arm. The reference arm consisted of a series of glass plates for dispersion
control and a mirror reﬂecting the light backward. The sample arm consisted of a
two-dimensional scanning mirror (Thorlabs, GVSM002) and an objective lens
(effective numerical aperature¼ 0.04; Zeiss) to focus the light on specimens. The
lateral resolution is estimated as 15 mm. The interfered light from the reference and
sample arm at the BS was collected by another optical ﬁbre and delivered to the
spectrometer for spectral acquisition. The mirror was scanning at a frequency of
2.56 kHz, and a 3D acquisition lasted 25.6 s with 256 by 256 pixels in two lateral
directions. The camera exposure time was 0.3 ms. With the bandwidth, the axial
resolution was estimated as 2 mm.
The depth structural reconstruction was created by the following steps. The
recorded spectrum was ﬁrst normalized by the source spectrum, and then
resampled into k domain with equal interval, and ﬁnally a Fourier transform was
taken to recover the depth signal. k is the wave number, deﬁned by k¼ 2p/l. The
calculation of D value was performed by the following steps. A Gaussian window
with width kw¼ 0.36 mm 1 was applied on the spectrum, and the depth structural
reconstruction process was performed. This process was then repeated with the
Gaussian window scanning through the whole spectral range, and the wavelength-
dependent 3D structure was obtained. The reduced range of spectrum relaxed the
axial resolution to be about 20 mm. The averaged spectra from the specimen were
modelled by I(k)¼ k2-D/2. The value of D was then obtained by calculating the
power of the spectra.
Statistical analysis. Data are presented as mean±s.e.m., and P values were
determined using a Mann–Whitney test for single comparisons. For comparison of
relative numbers of mice containing metastasis to various tissues, a Fisher’s exact
test was used to determine the P value. Statistical analysis was performed using
GraphPad Prism.
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